Typically, gene transfer strategies utilize a promoter/transgene arrangement that treat these elements independently and do not offer any interplay between them. Our goal was to establish a promoter/transgene combination that would result in improvement in both expression and therapeutic effect by utilizing the transcriptional properties of p53 to drive its own expression as well as act as a tumor suppressor. The pCL retroviral system was modified in the U3 region of the 3 0 LTR by the addition of a p53-responsive sequence (the PG element), creating the pCLPG system. Upon reverse transcription, the 5 0 LTR is converted, as shown here, to a p53-dependent promoter. We also show, using a temperature-sensitive model, that the pCLPG system could be driven by p53 encoded within the virus construct and expression was modulated depending on the p53 phenotype, demonstrating a regulatory feedback loop. Moreover, the pCLPG system was shown to express the transgene at a higher level and to inhibit tumor cell proliferation more robustly than the original pCL system. This novel system employs the transgene to serve two purposes, drive viral expression and inhibit tumor cell proliferation. The pCLPG vectors represent a new gene transfer strategy of synergizing the promoter and transgene activities. Cancer Gene Therapy (2005) 12, 935-946.
R etroviral vectors have been widely used in both the laboratory and the clinic as gene transfer vehicles. One of the attractive features of retroviral vectors is the ease with which regulation of viral expression may be modified. However, such strategies usually rely on cellular factors to promote viral expression, for example, when establishing tissue-specific expression.
The viral long terminal repeat (LTR) may be used to drive transgene expression, a potential advantage since LTR-mediated expression is quite strong in a wide variety of cell types. In addition, the LTR is easily modified, permitting cell type-specific transcriptional control, increased expression levels, or prolonged in vivo expression. Alterations in the U3 region, containing the enhancer and negative control elements, of the 3 0 LTR result in conversion of the 5 0 LTR following reverse transcription. Replacement of the enhancer region with heterologous transcription factor target sequences can alter both the level of viral expression as well as alter the spectrum of cells capable of expressing that virus. For example, replacement of the enhancer region with a polyoma virus enhancer (PyF101), 1,2 tetracycline-responsive elements (TRA99), 3 cytomegalovirus immediate-early enhancer (CMV-IE), 4 CD4 silencer, 5 or regulatory sequences from the prepro-endothelin-1 (ppET1) promoter 6 have resulted in altered viral expression patterns, including cell-type restricted expression (ppET1, CD4 silencer), repressible expression (TRA99) or expression in a wider range of cell types (PyF101, CMV-IE). The strategy of altering the LTR in order to change retroviral expression patterns is also effective for lentivirus-based vectors. 7, 8 These studies show that the LTR is quite malleable and can be modified to generate high-level, regulated or cell-specific expression.
The p53 tumor suppressor gene is one of the most frequently altered genes in human cancer. 9 In a normal cell, p53 protein levels are quite low, but upon stress or DNA damage, the p53 protein is stabilized and becomes active. 10 The activity of the wild-type p53 protein includes transcriptional activation of key cell cycle and proapoptotic control genes, such as p21Waf1 11 and bax, 12, 13 as well as the p53 antagonist, mdm2. [14] [15] [16] Transcriptional activation by p53 is mediated via direct binding to a known DNA motif present in the regulatory elements of target genes. 11, 17 P53 also suppresses expression from a variety of promoters, including antiapoptotic control genes, 13, 18 the multidrug resistance gene, 19, 20 and viral promoters, including the LTRs of HIV, RSV, and HTLV. 21 P53 is known to be a key regulator of apoptosis following radiation or treatment of cells with chemotherapeutic agents such as doxorubicin. 22, 23 Replacement of p53 activity in tumor cells has been shown repeatedly to halt cell proliferation as well as increase sensitivity to traditional cancer-fighting treatments.
One of the first p53-responsive elements to be identified was isolated from the ribosomal gene cluster (RGC). 24 In the PG13-CAT reporter construct, 13 copies of the RGC element were joined to a minimal promoter and the chloramphenicol acetyltransferase (CAT) cDNA, resulting in a highly sensitive p53-responsive regulatory unit. 25 In this study, we have altered retroviral expression by inserting the PG element into the U3 region of the 3 0 LTR of the pCL retrovirus, 26 establishing the pCLPG system, with the hope of gaining high-level expression driven by p53 in transduced cells. This method was preferred over the insertion of p53-responsive promoters, such as for the p21Waf1 gene, since these promoters may also act in a p53-independent fashion. 27, 28 We present here several distinct cell culture-based assays to demonstrate the functionality of the newly established pCLPG retroviral gene transfer system. This system includes viral vectors with the simple insertion of the PG element in the U3 region, an arrangement which maintains the native viral control elements, as well as the replacement of these regions with the PG element. In response to the DNA-damaging drug doxorubicin, the pCLPG system was activated by the well-known p53 pathway. Exogenous p53 could also activate the pCLPG system, demonstrated by the use of a temperaturesensitive mutant of p53, resulting in expression that surpassed that of the parental, nonmodified virus. Moreover, a feedback regulatory system was demonstrated when the pCLPG system encoded within the virus the cDNA for a temperature-sensitive mutant of p53. The combination of the p53-responsive LTR plus the wildtype p53 cDNA encoded by the virus yielded superior inhibition of tumor cell proliferation as compared to the parental virus system. We propose that this new concept in gene transfer, the interplay between the therapeutic gene and the viral promoter, will prove to be advantageous.
Materials and methods

Parental vectors
The Moloney Murine Leukemia Virus (MMLV)-based pCL and pCL-amphotropic packaging vectors are described in Naviaux et al. 26 Construction of the pCLPG system by insertion of the p53-responsive element into the viral LTR The establishment of the pCLPG system as well as the insertion of the chloramphenicol acetyltransferase cDNA have been described previously. 29 
Construction of the pCLPGEGFP series
The 800 bp EGFP cDNA was isolated from the pEGFP-N1 vector (Clontech, Palo Alto, CA) as a SacII-NotI fragment and inserted in the SacII-NotI sites of pBluescript to create the pBS-EGFP vector. The EGFP cDNA was then reisolated as an 800 bp BamHI fragment and inserted into the BamHI site of the pCL, pCLPG þ , pCLPGÀ, pCLPG þ DU3, and pCLPGÀDU3 vectors. Clones were isolated containing the EGFP cDNA in the proper orientation, yielding the pCLEGFP, pCLPG þ EGFP, pCLPGÀEGFP, pCLPG þ DU3EGFP, and pCLPGÀDU3EGFP constructs (pCLPGEGFP series).
Construction of the pCLPGp53(143) series
The cDNA for the human temperature-sensitive p53 30 was isolated as a 1.8 kb BamHI fragment from the pCMVp53(143) vector (kindly provided by Bert Vogelstein, Johns Hopkins University, Baltimore, MD) and inserted into the BamHI site of the pCL, pCLPG þ , pCLPGÀ, pCLPG þ DU3, and pCLPGÀDU3 vectors. Clones were isolated containing the p53(143) cDNA in the proper orientation, yielding the pCLp53(143), pCLPG þ p53(143), pCLPGÀp53(143), pCLPG þ DU3p53(143), and pCLPGÀDU3p53(143) constructs (pCLPGp53(143) series).
Construction of the pCLPGp53(wt) series
The cDNA for the human wild-type p53 was isolated as a 2.2 kb BamHI fragment from pCLp53(wt) 31 and inserted into the BamHI site of the pCLPG þ , pCLPGÀ, pCLPG þ DU3, and pCLPGÀDU3 vectors. Clones were isolated containing the p53(wt) cDNA in the proper orientation, yielding the pCLp53(wt), pCLPG þ p53(wt), pCLPGÀp53(wt), pCLPG þ DU3p53(wt), and pCLPGÀ DU3p53(wt) constructs (pCLPGp53(wt) series).
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell line 293T 32 was utilized for virus production. To test the pCLPG system, we used cells harboring wild-type p53 (HT1080, C6 and B16F10), mutant p53 (DU145, U251, T98G) or lacking p53 (Saos-2, PC3, H358). All cells (with the exception of B16F10) were maintained in complete medium DMEM (Invitrogen Life Technologies) supplemented with 10% fetal bovine serum (FBS, HyClone, Logan), 100 mg/ml gentamycin, 50 mg/ml ampicillin, and 2.5 mg/ml fungizone, at 371C, in a humidified atmosphere of 5% CO 2 . For B16F10, RPMI (Invitrogen Life Technologies) was used.
HT1080 cells were transduced with the pCLPGCAT series and selected with 800 mg/ml G418 (Invitrogen Life Technologies), then maintained with 400 mg/ml G418 in complete medium, creating the HT1080-pCLPGCAT series of cell lines. Saos-2 cells were transduced with the pCLPGEGFP or pCLPGCAT series of viruses and selected with 800 mg/ml G418, then maintained with 400 mg/ml G418 in complete medium, creating the SaospCLPGEGFP and Saos-pCLPGCAT series of cell lines.
A second transduction was then performed with the pBabep53(135)puro virus supernatant (see below) and cells were selected with 0.5 mg/ml puromycin (Sigma) in the presence of 400 mg/ml G418 in complete medium, creating the Saos-pCLPGEGFP/p53(135) and SaospCLPGCAT/p53(135) series of cell lines. In a separate experiment, Saos-2 cells were transduced with the pCLPGp53(143) series of viruses and selected with 800 mg/ml G418, then maintained with 400 mg/ml G418 in complete medium, creating the Saos-pCLPGp53(143) series of cell lines.
Virus production
To produce virus-containing supernatant in all cases, the indicated viral and amphotropic packaging vectors were cotransfected in 293T cells as described. 26, 33, 34 After 24 hours of incubation, the virus was collected, centrifuged for 5 minutes, 1000 rpm, then the supernatant removed and stored at À701C. The pBabep53(Val135)puro retroviral vector (kindly provided by Moshe Oren, Weizmann Institute, Rehovot, Israel) encodes the mouse temperature-sensitive allele of p53 35 as well as the puromycin resistance gene. Viral supernatant was produced as per the pCL-based vectors by cotrasfecting the pCL-Ampho packaging construct along with pBabep53(Val135)puro. The titer of virus-containing supernatants was assessed according to Bajgelman et al. 34 
CAT assays, Western and Northern blots
These assays were performed as per Strauss and CostanziStrauss 29 with the following exceptions: Western blots for the HT1080-pCLPGCAT series utilized a subconfluent 10 cm dish of each cell line treated overnight with complete medium plus 100 ng/ml of doxorubicin and an additional dish incubated in parallel, with no drug treatment, and all lines were maintained at 371C. Saos-2 cells transduced and selected with the pCLPGp53(143) series of vectors were plated at a density of 80%, 4-10 cm dishes for each line. The next day two dishes of each line were transferred to a 321C incubator and the other two dishes maintained at 371C for 72 hours. The cells were lysed in 1 ml of lysis buffer and samples processed. 29 For the Northern blots of the HT1080-pCLPGCAT series, 2-10 cm dishes of each cell line were treated overnight with complete medium plus 100 ng/ml of doxorubicin and an additional two dishes incubated in parallel, with no drug treatment, and all lines were maintained at 371C. The Saos-pCLPGp53(143) series of cell lines was plated at 80% density in 6-10 cm dishes for each line. Three dishes of each line were maintained at 32 or 371C for 72 hours before purification of total RNA using Trizol reagent (Invitrogen Life Technologies) according to the manufacturer's instructions or lysis to recover protein and samples were analyzed. 29 
Colony formation assay
The indicated cell type was plated, 2 Â 10 5 cells/well in sixwell dishes, and transduced the following day with equal quantities and concentrations of the pCL, pCLp53(wt) and pCLPGÀDU3p53(wt) viruses (4 Â 10 5 particles in 600 ml) or mock transduced in the presence of polybrene, 8 mg/ml. After 4 hours incubation at 371C, the virus supernatant was replaced with fresh medium. The next day, cells were harvested, counted, and replated at 7.5 Â 10 3 , 1.0 Â 10 4 , 2.5 Â 10 4 , and 5.0 Â 10 4 cells/dish in 6 cm dishes. The following day, the medium was replaced with fresh, complete DMEM containing 800-1000 mg/ml of G418 and cells were incubated until mock transduced cells had died, about 7 days. Then, medium was replaced and colonies allowed to form until clearly visible, usually an additional 7-14 days. After staining with Giemsa, easily distinguished colonies were counted for each of at least two independent experiments and mean and SD calculated, where the number of colonies in the pCL sample was considered as 100%.
Results
Construction and production of pCLPG retroviral vectors
In order to generate retroviruses with p53-driven expression, the PG element (13 copies of the p53-responsive element derived from the ribosomal gene cluster) was isolated from the PG13-CAT reporter construct 25 and inserted in the U3 region of the 3 0 LTR of the MMLVbased pCL retrovirus 26 as described previously. 29 We tested four distinct PG/LTR arrangements with the intention of achieving maximum expression levels. The pCLPG system encompasses the simple insertion of the PG element in both the sense and antisense orientations within the U3 region (pCLPG þ , pCLPGÀ) or the deletion of the enhancer/negative control regions from the LTR and replacement with the PG element in both the sense and antisense orientations (pCLPG þ DU3, pCLPGÀDU3). The cDNA's for chloramphenicol acetyltransferase (CAT), enhanced green fluorescent protein (EGFP), human wild-type p53 or the temperaturesensitive mutant of human p53 (p53(143)) were inserted in the modified vectors as well as the nonmodified pCL vector to serve as controls. As seen in Table 1 , a similar range of viral titer, as determined by G418 resistance, was obtained from either the pCLPG or parental pCL vectors.
Expression of the pCLPG system is regulated by p53 in response to DNA damage
We have previously shown that expression from the pCLPG system is indeed regulated by p53. 29 To test the response of the pCLPG system to p53 in a biologically relevant manner, HT1080 (wild-type p53) human fibrosarcoma cells were transduced with the pCLPGCAT series of virus and selected for G418 resistance. These cells were then treated with the DNA-damaging chemotherapeutic agent doxorubicin in order to activate endogenous p53 and induce expression from the pCLPG system (Fig 1a) . As seen in Figure 1b , CAT activity was elevated up to 2.2-fold for the PG-modified vectors in the presence of doxorubicin and surpassed the level of expression from the nonmodified LTR by nearly three-fold in the case of pCLPGÀDU3CAT. In the absence of drug treatment, significant expression from the modified vectors was apparent, most likely due to the basal activity of endogenous p53. Expression from the parental, nonmodified virus decreased slightly with drug treatment, consistent with published observations that p53 suppresses expression from some LTRs. 21 These results suggest that a drug treatment known to activate p53 also increased reporter gene activity expressed by the modified vectors and, in some cases, exceeded that of the parental virus.
To confirm these results at the transcriptional level, a Northern blot was performed using total RNA isolated from the HT1080-pCLPGCAT series of cell lines incubated with or without doxorubicin. Drug treatment clearly induced LTR-driven expression from the modified vectors, but slightly reduced expression from the parental construct, as determined with either the CAT or Neo probes (Fig 1c) . Note that the migration of the transcripts reflects the alteration in size due to the addition of the transgene as well as modification of the LTR. Probing for b-actin revealed that the alterations in transcript abundance were not simply due to differences in gel loading. These results indicate that drug treatment increased viral expression at the transcriptional level when the p53-responsive PG element was present in the viral LTR.
Western blot analysis of the drug-treated HT1080-pCLPGCAT series of cell lines revealed increased levels of p53 protein as compared to the nontreated cells (Fig 1d) . In addition, the p53 transcriptional target p21Waf1 was also increased in response to drug treatment, presumably through the well-known p53-activation pathway. Blotting for b-actin revealed that gel loading was not responsible for the observed differences in protein levels. Taken together, these results indicate that drug treatment activated endogenous p53 and increased expression from the PG-modified vectors that, in some cases, surpassed that of the parental system.
Expression from the pCLPG system in response to p53 provided in trans Next, we wished to compare the basal versus induced expression from the pCLPG system when p53 was provided by an expression vector in order to demonstrate the range of expression by the pCLPG system as well as its specificity for transcriptional activation by p53. The Saos-2 (p53À/À) human osteosarcoma cell line was transduced with the pCLPGEGFP or pCLPGCAT series of viruses at a multiplicity of infection (MOI)r1and selected for G418 resistance, establishing the SaospCLPGEGFP and Saos-pCLPGCAT series of cell lines. In order to supply p53 to these cells, a temperaturesensitive mutant of murine p53 35 was introduced via a second retroviral transduction using the pBabep53 (Val135)puro retrovirus followed by selection with puromycin. Cells were then cultured at either 371C, where p53 adopts a mutant conformation and is unable to activate transcription, or at 321C, where p53 assumes wild-type conformation and activity (Fig 2a) . Cells were collected after 5 days of temperature conditioning and analyzed for reporter gene activity. Expression of p53(135) at 32 and 371C was confirmed by Western blot analysis (data not shown).
Expression from the pCLPGEGFP series of virus was measured in the Saos-pCLPGEGFP and SaospCLPGEGFP/p53(Val135) series of cell lines. All PGmodified vectors exhibited low expression in the absence of wild-type p53 activity and an increased average intensity of EGFP fluorescence in the presence of wildtype p53 activity (Fig 2b) . Expression from the nonmodified pCLEGFP virus was not significantly altered by the temperature or presence of p53. Strikingly, the average fluorescence intensity from the modified virus was three-to four-fold greater than the nonmodified virus. No expression was measured from the pCL-negative control regardless of temperature or presence of p53. These results indicate a low-level basal expression of the pCLPG system in the absence of p53 activity, yet p53-stimulated expression levels from the pCLPG vectors were stronger than that of the parental pCL virus in Saos-2 cells.
Similarly, measurement of viral expression with the CAT reporter gene in the temperature-sensitive system revealed p53-specific expression that surpassed the level of expression seen in the parental virus (Fig 2c) . Notably, the PG-modified vectors were induced in the presence of wildtype p53 activity (at 321C). In the absence of p53 activity, negligible background expression was observed from the pCLPG þ CAT or pCLPGÀCAT vectors, yet leaky expression was evident for the pCLPGÀDU3CAT vector at both 32 and 371C and the pCLPG þ DU3CAT vector revealed background expression only at 321C. Expression pCLPG combines promoter and transgene activities BE Strauss et al from the pCLPGÀDU3CAT vector was measured to be nearly seven-fold greater than the nonmodified parental pCLCAT vector.
Taken together, these experiments demonstrate that expression from the pCLPG system is driven specifically by wild-type p53, that the function of the PG element is a b c Figure 2 p53-dependent expression of the pCLPG system confirmed by detection of the EGFP and CAT reporter genes. (a) A temperaturesensitive system was established in order to test the specificity of the pCLPG system for p53 as well as compare the basal versus. induced expression levels. Saos-2 cells (p53À/À human osteosarcoma) were transduced with the pCLPGEGFP or pCLPGCAT series of virus, selected for G418 resistance, then retransduced with the pBabep53(135)puro virus and selected for puromycin resistance while in the continued presence of G418, resulting in the generation of 22 distinct cell lines. (b) Results of flow cytometry detection of EGFP induced by a temperature-sensitive mutant of p53. The Saos-pCLPGEGFP series of cell lines was incubated at either 321C (white bars) or 371C (striped bars) and the SaospCLPGEGFP/p53(135) series of cell lines was likewise incubated at 321C (black bars) or 371C (stippled bars) for 120 hours before harvest for analysis by flow cytometry. The histogram represents the mean intensity of EGFP fluorescence expressed as arbitrary units of intensity, as measuremed by the FACS software, from two independent experiments. Lanes 1-6 refer to the specific vector of the pCLEGFP series (pCL, pCLEGFP, pCLPG þ EGFP, pCLPGÀEGFP, pCLPG þ DU3EGFP, pCLPGÀDU3EGFP , respectively). (c) CAT activity measured after induction of the pCLPG system by a temperature-sensitive mutant of p53. In a manner analogous to panel (b), the Saos-pCLPGCAT series of cell lines was incubated at 321C (white bars) or 371C (striped bars) and the Saos-pCLPGCAT/p53(135) series of cell lines was incubated at 321C (black bars) or 371C (stippled bars) for 120 hours before havesting of cells and analysis of CAT activity. The histogram represents the mean percentage of conversion of chloramphenicol to the acetylated form, as determined by densitometric analysis of the autoradiographs, from two independent experiments. Lanes 1-6 refer to the specific vector of the pCLPGCAT series (pCL, pCLCAT, pCLPG þ CAT, pCLPGÀCAT, pCLPG þ DU3CAT, pCLPGÀDU3CAT , respectively).
pCLPG combines promoter and transgene activities BE Strauss et al retained even in the context of the LTR and that expression from the pCLPG system could surpass that of the parental, nonmodified virus. In the absence of p53 activity, the pCLPG system presents leaky expression, the degree of which is related to the specific PG/LTR arrangement.
Expression of the pCLPG system when p53 is provided in cis reveals a feedback regulatory mechanism
We wished to examine the possibility that a p53 cDNA encoded within the pCLPG virus could drive viral expression, referred to here as the cis arrangement since p53 is neither cellular nor encoded by a separate expression vector. In cells lacking functional p53, expression would be initiated by leaky transcription from the pCLPG system and would reach the full level of expression upon reiterative activation of the p53-responsive element by the virus-encoded p53. In other words, the activity of the modified promoter would operate in concert with wild-type p53 in order to establish a positive feedback regulatory mechanism. We tested this concept utilizing a temperature-sensitive mutant of human p53. Saos-2 cells were transduced with the pCLPGp53(143) series of virus and selected for G418 resistance. Viral expression is expected only if p53 is expressed and takes on the wild-type conformation (Fig 3a) . The Saos-pCLPGp53(143) series of cell lines were cultivated at either 37 or 321C for 72 hours, then lysates prepared, protein content measured, and an equal amount of protein from each lysate was subjected to an immunoprecipitation-Western blot assay (Fig 3b) . Cells cultured at 321C exhibited a drastic increase in p53 expression, especially from the four Saos-pCLPGp53(143) lines. At 371C, only a light band can be observed representing p53(143) expressed by the nonmodified pCL vector, whereas no p53 was detected in the four different Saos-pCLPGp53(143) lines and none from the Saos-pCL-negative control. Unexpectedly, the p53 expression from the pCLp53(143) virus also appeared to increase at the lower temperature, though to a lesser extent than the PG-modified vectors, possibly due to stabilization of the protein.
To confirm the transcriptional activity of the pCLPGencoded p53(143), the cell lysates from the p53 immunoprecipitation-Western assay were reprecipitated for p21Waf1, a transcriptional target of p53, 11 using a specific antibody and visualized by Western blot analysis (Fig 3b) . In cells cultured at the permissive temperature, the expression of p21Waf1 was strongly increased only in lines which harbored exogenous p53(143). In contrast, the p53 (143) p53 (143) p53 ( Figure 3 Expression driven by p53 encoded within the pCLPG system was detected by Western and Northern blot analyses, revealing a positive feedback regulatory mechanism. (a) We tested expression of p53 encoded by the pCLPG system, the cis arrangement, by establishing a temperature-sensitive system. Saos-2 cells were transduced with the pCLPGp53(143) series of vectors and selected for G418 resistance. Cells were maintained at 371C for the selection and expansion process. Then a portion of each was transferred to 321C and a portion was maintained in parallel at 371C. For both (b) and (c), lanes 1-6 refer to the specific vector of the pCLPGp53(143) series (pCL, pCLp53(143), pCLPG þ p53(143), pCLPGÀp53(143), pCLPG þ DU3p53(143), pCLPGÀDU3p53(143), respectively). (b) After 3 days incubation, cell lysates were prepared, protein content determined, and an equal quantity (1.3 mg) of each lysate was incubated with the PAb 421 p53-specific monoclonal antibody, precipitated with protein-A agarose, and the immune complex analyzed by Western blot using the PAb 421 antibody. The same lysate used for the detection of p53 was also analyzed by this immunoprecipitation-Western blot technique for the expression of p21Waf1, and b-actin as a loading control. (c) Northern blot analysis reveals p53-dependent expression of the pCLPG system at the transcriptional level. For this assay, the cells were cultivated as described above, then total RNA was isolated and subjected to Northern blot analysis. The probes used were the labeled, full-length cDNA's of p53, neomycin resistance gene (Neo R ), or b-actin. The membrane was stripped between probes, thus a single membrane was used sequentially for all of the hybridizations shown.
pCLPG combines promoter and transgene activities BE Strauss et al expression of p21Waf1 was low at 371C due to the absence of functional p53 and was consistent among all of the Saos-pCLPGp53(143) lines. The p21Waf1 expression at 32 and 371C was unaltered in the absence of p53, indicating that this protein does not suffer alteration in stability due to temperature. As a control for loading a third Western blot, this time for b-actin, was performed using the lysates already analyzed for p53(143) and p21Waf1 expression.
Northern blots of total RNA recovered from the SaospCLPGp53(143) series of cell lines maintained at either 32 or 371C confirm an increase in transcription in the modified vectors in the presence of wild-type p53 activity. As seen in Figure 3c , p53 expression from the pCLPGp53(143) vectors was detected by the p53-specific probe only at 321C when the p53(143) protein took on wild-type activity. In contrast, transcripts at similar levels of expression from the nonmodified pCLp53(143) vector at both 32 and 371C, confirming the p53 and temperatureindependent expression of the parental vector and suggesting that the increased p53 detected in the SaospCLp53(143) cells at 321C was most likely due to stabilization of the protein and not from altered transcription. As expected, no transcripts were detected from the pCL vector not encoding p53.
These results were confirmed by stripping the blot and re-probing with a neomycin resitance gene (Neo R )-specific probe (Fig 3c) . The pCLPGp53(143) series of vectors expressed the LTR-driven transcript at 321C, but not at 371C, confirming that wild-type p53 activity was necessary to drive expression from the modified LTR. As expected, all pCL and pCLPG vectors revealed a Neo R transcript driven by the internal SV40 promoter at either 32 or 371C. Also as expected, the pCL and pCLp53(143) vectors revealed an LTR-driven transcript at both 32 and 371C. Stripping and reprobing for p21Waf1 demonstrated an increase in transcripts only when p53 was present and in the wild-type conformation (data not shown). Stripping and reprobing for b-actin revealed that the differences in transcript levels were not due to alterations in RNA loading in the gel (Fig 3c) .
Therefore, we have shown at the transcriptional level that the pCLPG system is indeed driven by wild-type p53 activity when provided in cis. These results reveal a feedback regulatory mechanism that is initiated, presumably, by leaky basal transcription of the pCLPG system. In addition, modulation of the p53 phenotype resulted in the modulation of viral expression, demonstrating the feedback concept.
The strategic combination of promoter and transgene activities reveals decreased tumor cell proliferation as measured in a clonogenic assay Finally, we wished to test the idea that the juxtaposition of a p53-responsive promoter with the p53 cDNA would yield improved inhibition of tumor cell lines. In this case, the pCLPG system encoding wild-type human p53 may offer both improved viral expression as well as improved p53-mediated inhibition as compared to the simple, constitutive expression of p53 driven by the native LTR (Fig 4a) . The pCLPGÀDU3 construct was chosen for this experiment since it presented the highest apparent level of expression in our assays.
Tumor cell lines with either no, mutant or wild-type p53 were transduced with equal quantities of the empty, parental pCL virus or the viruses encoding wild-type human p53, pCLp53(wt) or pCLPGÀDU3p53(wt). After selection with G418, colonies of resistant cells were scored and the inhibition of proliferation by p53 revealed. As shown in Figure 4b , the pCLPGÀDU3p53(wt) virus more efficiently inhibited colony formation as compared to the parental virus for the majority of cell lines (8/9) . Strikingly, the modified vector was associated with inhibited tumor cell proliferation in six lines that were highly resistant to the effects of p53 expressed from the parental virus (Saos-2, PC3, T98G, DU145, C6, and B16). These assays also revealed that the status of endogenous p53 was not predictive for inhibition by exogenous p53 delivered by either viral system. The pCLPG-DU3p53(wt) virus was able to inhibit proliferation to a level of 50% or more in 8/9 lines, yet the parental pCLp53(wt) virus performed at this level in only 3/9 lines. Overall, the strategic combination of promoter and transgene activity present in the pCLPG system did reveal improved, even if not complete, inhibition of tumor cell lines as compared to the parental system in this assay.
Discussion
We have constructed a novel retroviral gene transfer system, which pairs transcriptional control with transgene activity. In the presence of wild-type p53 activity, the expression from the pCLPG system was nearly seven-fold greater than the parental pCL system in the transduced cell. These findings were tested at the functional level by reporter assays, at the protein level by Western blots and at the transcriptional level by Northern blots. An intriguing observation was the ability of the pCLPG system encoding wild-type p53 to inhibit proliferation of many tumor cell lines that were refractory to the parental system.
We studied four distinct arrangements of the PG element within the U3 region of the LTR and observed only slight differences. For example, the pCLPGÀDU3 arrangement consistently yielded the highest level of expression, but the CAT assays revealed a higher background for this vector in the absence of functional p53. The pCLPG þ and pCLPGÀ vectors presented minimal background, but also slightly reduced expression in the presence of functional p53. Interestingly, addition of the p53-responsive element in the U3 region was sufficient to abolish expression mediated by the native enhancer element. For applications where maximum expression is desired, the pCLPGÀDU3 vector may be the best suited, but tightly regulated control of expression may best be achieved by the pCLPG þ vector. The results of the clonogenic assay (Fig 4) suggest that the activity of the pCLPG system encoding wild-type p53 is independent of endogenous p53 status since the inhibition of cells containing no, mutant or wild-type p53 was achieved. Strikingly, the pCLPG system was shown to inhibit colony formation of six cell lines that were refractory to the parental system. Since inhibition was generally incomplete, other factors may still be necessary to complement p53 activity, such as p14Arf. 37, 38 Mdm2, an antagonist of p53 function and E3 ubiquitin ligase that promotes p53 degradation, 16 may reduce the efficiency of the pCL and pCLPG systems, contributing to the incomplete inhibition observed here. The possible role of the p53 family members, p63 and p73, in the function of the pCLPG system have not yet been addressed.
Our results imply that even low level, leaky expression of p53 encoded within the pCLPG system was sufficient to activate high-level expression in the p53-null Saos-2 cell line. This suggests that, in the case of pCLPG-mediated p53 gene transfer to p53-null cells, the activation of expression would be initiated by the p53 encoded by the virus itself. In the case that the target cells harbor mutant p53, it is possible that a dominant-negative effect of the mutant over the wild-type p53 would be established. However, we have observed that an extreme excess of mutant p53 is required and, in that case, did not completely inhibit wild-type activity. 39 Given the highlevel expression from the pCLPG system, we believe that sufficient wild-type p53 expression could be established such that the mutant p53 activity would be quenched and wild-type activity would prevail. Moreover, only a subset of p53 mutants act in a dominant-negative manner, 39 thus the range of cell types that support the pCLPG system is expected to be quite ample.
The pCLPG system has several inherent safety features. For example, expression is limited to cells that express wild-type p53, whether endogenous or exogenous. Loss of p53 due to mutation would result in a shut-down of pCLPG expression. In the case that the modified virus encodes the p53 cDNA, mutation of this cDNA would result in the loss of its expression. Constitutively active promoters, such as CMV or the nonmodified LTR, would continue to express the transgene even after it had mutated. This is certainly not a desirable feature in a gene transfer system, as recently observed in an adenoviral system. 40 We have shown here that the temperaturesensitive mutant of human p53, when encoded by the pCLPG system, mediated viral expression only at 321C, when the protein adopts the wild-type conformation. Thus, modulation of the p53 phenotype revealed a feedback mechanism for the regulation of pCLPG expression.
Given recent events indicating the development of leukemia due to retroviral insertion in both patients and an animal model, 36, [41] [42] [43] [44] it is tempting to speculate how the pCLPG system would impact neighboring genes after insertion in the host genome. Since the pCLPG system depends on p53 to drive expression, it stands to reason that activation of genes neighboring the insertion point would also be elevated in the presence of p53. In the case that an oncogene is activated, the functions of that oncogene and p53 may then be in opposition.
The pCLPG system extends the versatility of the original pCL retrovirus. The parental pCL system aids in the production of virus encoding cytotoxic or cytostatic genes, yet the virus that is produced is functionally equal to other moloney murine leukemia virus (MoMLV)-based systems. With the addition of the PG element in the 3 0 LTR, the production strategy of the pCLPG system retains the benefits offered by the chimeric 5 0 LTR in the transfected cell, yet viral transcription, in cells transduced by the progeny, will be controlled by p53. In this way, the pCLPG system offers transcriptional levels that may exceed standard MLV systems in both the packaging and transduced cells.
We envision several applications of the pCLPG system. The pCLPG system may serve as a reporter construct for the measurement of p53 activity. This may be advantageous since the retrovirus can transduce a wide variety of cells both in vivo and in vitro. We have shown here that the pCLPG system may serve to measure wild-type p53 activity, such as in response to genotoxic stress, or the lack of p53 activity, such as in p53-null or mutant p53 cells, demonstrating the utility of the pCLPG system as a reporter of endogenous p53 activity.
Since genotoxic drugs activate endogenous p53, the pCLPG system may prove to be useful as a gene transfer vehicle in the clinical setting. Retroviral transduction of HSC's with MDR1 45 has been extensively studied and attempted clinically, but with generally disappointing results due to low transduction efficiencies and lack of expression of the transgene, 46 ,47 though improved transduction protocols and a modified MDR1 cDNA have partially remedied this situation. 48, 49 Additional advantages may be offered in the case of pCLPG-mediated delivery of the MDR1 cDNA since a drug used for chemotherapy, and which activates p53, should, in turn, activate MDR1 expression from the pCLPG virus in the hematopoietic cells, protecting and selecting them for continued proliferation.
We are studying the effects of wild-type p53 encoded within the pCLPG system on xenograft models of tumor formation. In this case, we expect p53 to act in two separate capacities: (1) To drive viral expression of p53 to very high levels, and (2) to inhibit tumor growth due to the tumor suppressor functions of p53. In this way p53 would be called upon to aid in both the gene transfer and tumor fighting strategies.
In summary, we have established a p53-driven retroviral gene transfer system. Expression from the pCLPG system was stronger than that observed from the nonmodified parental pCL system and exhibited a low level of background expression in the absence of functional p53. We believe that the pCLPG system will prove to be a useful tool for both gene transfer and p53-related studies. Moreover, we present here a novel gene transfer strategy, the interplay of promoter and transgene activities.
